Spironolactone in Diabetic Nephropathy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.
Epistemonikos ID: 2d58f993002fb08e9165402ad374255040e01692
First added on: May 04, 2024